A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
NCT ID: NCT04597918
Last Updated: 2023-12-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
99 participants
INTERVENTIONAL
2020-11-25
2022-12-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Faricimab
Participants will receive 6 doses (one 6 mg faricimab intravitreal \[IVT\] injection every 28 days \[Q4W\]) starting at Day 1 and ending on the Day 140 visit. Participants will return for a safety follow-up visit (SFV) after ≥28 days and within \<35 days following their last study treatment.
Faricimab
A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Faricimab
A 6-milligram (mg) dose of faricimab will be administered intravitreally (IVT) in the study eye once every 4 weeks (Q4W).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hemoglobin A1c (HbA1c) ≤10%
* Patients who are intravitreal (IVT) treatment-naïve in the study eye
* Diabetic macular edema (DME) defined as macular thickening by spectral-domain optical coherence tomography (SD-OCT) involving the center of the macula. This inclusion criterion is to be assessed by the central reading center (CRC).
* Decreased visual acuity (VA) attributable primarily to DME
* Clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images to confirm diagnosis
Exclusion Criteria
* Any known hypersensitivity to any of the components in the faricimab injection, dilating eye drops, or any of the anesthetics and antimicrobial preparations used by the patient during the study
* Any major illness or major surgical procedure within 1 month before the Day 1. One re-screening for this criterion is permitted
* History of other diseases, other non-diabetic metabolic dysfunction, physical examination finding, historical or current clinical laboratory finding giving reasonable suspicion of a condition that contraindicates the use of the faricimab or that might affect interpretation of the results of the study or renders the patient at high-risk for treatment complications, in the opinion of the Investigator
* Active cancer within the past 12 months prior to Day 1 except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and prostate cancer with a Gleason score of ≤6 and a stable prostate-specific antigen for \>12 months
* Stroke or myocardial infarction within 12 months prior to the Day 1. One re-screening for this criterion is permitted
* Any febrile illness within 1 week prior to Day 1. One re-screening for this criterion is permitted
* Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of faricimab
* Renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis within 6 months prior to Day 1 or anticipated to require hemodialysis or peritoneal dialysis at any time during the study
* Any condition resulting in a compromised immune system that is likely to impact the aqueous humor (AH) inflammatory biomarkers.
* Patients who are currently enrolled in or have participated in any other clinical study involving an investigational product or device, or in any other type of medical research, within 3 months or 5 half-lives prior to Day 1 and up to completion of the current study
* Substance abuse occurring within 12 months prior to screening, in the Investigator's judgment
* Use of systemic immunomodulatory treatments within 6 months or 5 half-lives prior to Day 1
* Use of any systemic corticosteroids (including inhaled corticosteroids from inhalers used regularly, e.g., pulmonary disease, asthma, or seasonal allergy) within 1 month prior to Day 1
* Any prior or concomitant systemic anti-VEGF treatment within 6 months or 5 half-lives prior to Day 1
* Use of systemic medications known to be toxic to the lens, retina or optic nerve used during the 6-month period or 5 half-lives prior to Day 1 or likely need to be used
* Received a blood transfusion within 3 months prior to the screening visit
* Received any treatment that leads to immunosuppression within 6 months or 5 half-lives prior to Day 1
* High-risk PDR. This exclusion criterion is to be assessed by the CRC
* Any history of or ongoing rubeosis iridis
* Any panretinal photocoagulation or macular laser photocoagulation treatment received in the study eye prior to the screening visit or expected to be received between the screening visit and Day 1
* Any history of treatment with anti-VEGF or any periocular or IVT corticosteroids in the study eye and no such treatment planned for the time between screening and Day 1
* Any treatment for dry eye disease in the last month prior to Day 1. Lubricating eye drops and ointments are permitted.
* Any treatment with anti-inflammatory eye drops within 1 month prior to Day 1
* Any intraocular surgery within 3 months prior to Day 1 or any planned surgery during the study
* Any glaucoma surgery/laser procedure involving the iris, trabecular meshwork, or ciliary body prior to the screening visit. Only iris surgery/laser might be allowed if they occurred more than 6 months prior to Day 1.
* History of vitreoretinal surgery/pars plana vitrectomy, corneal transplant, or radiotherapy
* Any active or suspected ocular or periocular infections on Day 1
* Any presence of active intraocular inflammation on Day 1 or any history of intraocular inflammation
* Any history of idiopathic, infectious, or noninfectious uveitis
* Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision
* Any current ocular condition or other causes of visual impairment for which, in the opinion of the Investigator, VA loss would not improve from resolution of macular edema
* Patient is currently receiving treatment with brolucizumab or bevacizumab in the non-study eye and is unwilling to switch to a protocol allowed non-study eye treatment during the study
* Any previous treatment with Iluvien® or Retisert® in the non-study eye
* Non-functioning non-study eye
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bascom Palmer Eye Institute
Naples, Florida, United States
Northwestern Medical Group/Northwestern University
Chicago, Illinois, United States
University Retina and Macula Associates, PC
Oak Forest, Illinois, United States
Raj K. Maturi, MD PC
Indianapolis, Indiana, United States
Cumberland Valley Retina PC
Hagerstown, Maryland, United States
The Retina Institute
St Louis, Missouri, United States
Long Is. Vitreoretinal Consult
Hauppauge, New York, United States
Charles Retina Institute
Germantown, Tennessee, United States
Retina Res Institute of Texas
Abilene, Texas, United States
Austin Research Center for Retina
Austin, Texas, United States
Retina Consultants of Texas
The Woodlands, Texas, United States
Strategic Clinical Research Group, LLC
Willow Park, Texas, United States
Centro Oftalmológico Dr. Charles S.A.
Capital Federal, , Argentina
Oftalmos
Capital Federal, , Argentina
Vitreous Retina Macula Specialists of Toronto
Etobicoke, Ontario, Canada
The Retina Centre of Ottawa
Ottawa, Ontario, Canada
Universitätsklinikum Tübingen
Tübingen, , Germany
Ospedale San Giuseppe; U.O. Oculistica
Milan, Lombardy, Italy
Irccs Ospedale San Raffaele;U.O. Oculistica
Milan, Lombardy, Italy
Wojskowy Instytut Medyczny - Panstwowy Instytut Badawczy
Warsaw, , Poland
Gloucestershire Hospitals NHS Foundation Trust
Gloucestershire, , United Kingdom
Kings College Hospital
London, , United Kingdom
Sunderland Eye Infirmary
Sunderland, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-001174-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MR41926
Identifier Type: -
Identifier Source: org_study_id